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Background: Human cells release nano-sized vesicles called exosomes, containing mRNA, miRNA and specific
proteins. Exosomes from one cell can be taken up by another cell, which is a recently discovered cell-to-cell
communication mechanism. Also, exosomes can be taken up by different types of cancer cells, but the potential
functional effects of mast cell exosomes on tumor cells remain unknown.
Methods and results: Exosomes were isolated from the human mast cell line, HMC-1, and uptake of PKH67-labelled
exosomes by the lung epithelial cell line, A549, was examined using flow cytometry and fluorescence microscopy.
The RNA cargo of the exosomes was analyzed with a Bioanalyzer and absence or presence of the c-KIT mRNA was
determined by RT-PCR. The cell proliferation was determined in a BrdU incorporation assay, and proteins in the
KIT-SCF signaling pathway were detected by Western blot. Our result demonstrates that exosomes from mast cells
can be taken up by lung cancer cells. Furthermore, HMC-1 exosomes contain and transfer KIT protein, but not the
c-KIT mRNA to A549 cells and subsequently activate KIT-SCF signal transduction, which increase cyclin D1
expression and accelerate the proliferation in the human lung adenocarcinoma cells.
Conclusions: Our results indicate that exosomes can transfer KIT as a protein to tumor cells, which can affect
recipient cell signaling events through receptor-ligand interactions.
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Exosomes are nano-sized membrane vesicles (30–100
nm) constitutively released by various cells, such as B
lymphocytes [1], dendritic cells [2,3], mast cells [4], nat-
ural killer (NK) cells [5], intestinal epithelial cells [6],
tumor cells [7,8], and neuronal cells [9]. These extracel-
lular vesicles have a lipid bilayer structure, and carry
multiple proteins and RNA molecules [10]. Exosomes
are known to shuttle their cargo, including proteins and
lipids between cells [11], and in addition, we showed in
2007, that exosomes also shuttle functional RNA from
one cell to another [12]. Importantly, the transfer of* Correspondence: annylish@hotmail.com; jan.lotvall@gu.se
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unless otherwise stated.these molecules can change a recipient cell phenotype in
many ways, and the exosome-mediated signal from the
original cell may be different under different circum-
stances [13]. Exosomes are present in all human body
fluids so far investigated, including saliva [14], blood
plasma [15], breast milk [16], cerebrospinal fluid [17]
and urine [18], and are abundant in the tumor micro-
environment [19,20], indicating their importance for
tumor biology.
The human c-KIT oncogene codes for the protein
mast/stem cell growth factor receptor Kit (KIT), a mem-
ber of the tyrosine kinase family of growth receptors
[21]. KIT is expressed on a variety of hematopoietic
cells, such as mast cells and bone marrow progenitor
cells. Stem cell factor (SCF) dependent activation of KIT
is critical to maintain homeostasis and function of mast
cells [22]. In clinical lung cancer research, it has beend. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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to death if the tumor is KIT positive [23]. For example,
if tumors are positive for KIT at the time of surgery,
the disease is associated with short term survival, com-
pared to those that are KIT negative [24]. In addition, co-
expression of KIT and other tumor-promoting molecules
such as EGFR tend to increase mortality further [25]. Dur-
ing some circumstances it is less clear how tumor cells be-
come KIT positive, but one possibility is that non-tumor
cells in the tumor microenvironment could shuttle such
molecules between cells [26].
Tumors also harbor many other cells beside tumor
cells, including inflammatory cells such as dendritic cells
and mast cells [27,28], as well as fibroblasts and endo-
thelium [29,30]. Furthermore, co-cultures of mast cells
and non-small cell lung cancer leads to increased prolif-
eration of the cancer cells both in vitro and in vivo [31].
In this study we therefore hypothesized that KIT could
possibly be transferred to tumor cells via exosomes
from one or several of the surrounding cells. To test
this, we used a mast cell line (HMC-1) constitutively ex-
pressing the active form of the KIT receptor, and a non-
small cell cancer lung epithelial tumor cell line (A549),
to determine whether KIT can be transferred from mast
cells to the epithelial cancer cell via exosomes, and




The lung adenocarcinoma cell line, A549, was obtained
from the ATCC and the human mast cell line, HMC-1
(Dr Joseph Butterfield, Mayo Clinic, Rochester, MN, USA)
was a kind gift from professor Gunnar Nilsson at the
Karolinska Institute, Stockholm, Sweden. Control exo-
somes were derived either from the mouse embryonic
fibroblast cell line, NIH 3T3 (Cell lines service, Eppelheim,
Germany), or the human embryonic kidney 293 cell line,
HEK 293 (from ATCC and a kind gift from Jonas Nilsson
at the Sahlgrenska University Hospital, Gothenburg,
Sweden). HMC-1 cells were maintained in Iscove’s modi-
fied Dulbecco’s medium (IMDM; HyClone Laboratories,
Inc., Logan, UT, USA) supplemented with 10% exosome-
depleted fetal bovine serum (FBS), 100 units/ml penicillin,
100 μg/ml streptomycin, 2 mM L-glutamine and 1.2 mM
alpha-thioglycerol (all reagents were from Sigma-Aldrich,
St Louis, MO, USA). NIH 3T3 cells were maintained in
Dulbecco's modified Eagle medium (DMEM; HyClone
Laboratories) and HEK 293 cells were maintained in
Eagle's Minimum Essential Medium (EMEM, HyClone
Laboratories), both medium were supplemented with 10%
exosome-depleted FBS, 100 units/ml penicillin, 100 μg/ml
streptomycin, 2 mM L-glutamine and 110 μg/ml sodium
pyruvate (Sigma-Aldrich). The exosome-depleted FBS forthe HMC-1, HEK 293 and NIH 3T3 cell cultures, was
obtained by ultracentrifugtion at 120,000 × g for 18 hours
using a Ti45 rotor (optima L-90 k Ultracentrifuge, Beckman
Coulter, Brea, CA, USA). A549 cells were routinely main-
tained in DMEM/F-12 K medium (HyClone Laboratories,
Inc.) supplemented with 10% FBS, 100 units/ml penicillin
and 100 μg/ml streptomycin. All cells were cultured at
37°C in a humidified atmosphere of 5% CO2.
Isolation of exosomes
Exosomes were isolated from the supernatant of HMC-1,
HEK 293 and NIH 3T3 cells by differential centrifugation
and a filtration step as described by Lässer et al. [32]. In
brief, cell supernatant were harvested, centrifuged at
300 × g for 10 minutes to eliminate cells and at 16,500 × g
for 20 minutes, followed by filtration through 0.2 μm fil-
ter (Sarstedt, Numbrecht, Germany) to eliminate cellu-
lar debris and larger vesicles. Exosomes were pelleted
by ultracentrifugation at 120,000 × g for 70 minutes.
Exosomes were measured for their protein content
using the BCA protein assay kit (Thermo Scientific
Pierce, Rockford, IL, USA).
Electron microscopy
Isolated exosomes from HMC-1 cells were resuspended in
PBS, and loaded onto UV-light pre-treated formwar/
carbon-coated nickel grids (Ted Pella Inc., Redding, CA,
USA). The exosomes were pre-fixed in 2% paraformal-
dehyde, before immuno-staining with anti-human CD63
antibody (BD Biosciences, San José, CA, USA). The exo-
somes were then immuno-stained with a 10 nm gold-
labelled secondary antibody (Sigma-Aldrich) prior to being
post- fixated in 2.5% glutaraldehyde and contrasted in 2%
uranyl acetate. Preparations were examined in a LEO
912AB Omega electron microscope (Carl Zeiss Jena
GmbH, Eching, Germany).
Uptake of HMC-1 exosomes by A549 cells
To monitor uptake kinetics, exosomes derived from
HMC-1, as well as the control cells HEK 293 and NIH
3T3 cells, were labelled with the green fluorescent dye
PKH67 (Sigma-Aldrich) according to the adjusted proto-
col outlined in Lässer et al. [14]. Briefly, 20 μg of the
PKH67-stained exosomes were washed five times using
300 kDa Vivaspin filters (Sartorius AG, Göttingen,
Germany) to remove excess dye and then added to 2 ×
105 A549 cells in culture. Cells were harvested at differ-
ent time points (1, 2, 4, 8, 12, 24 and 48 hours), washed
three times and analyzed by flow cytometry using a BD
FACSAria (BD Biosciences). Additionally, cells were vi-
sualized at 8 or 12 hours with a fluorescence microscopy
(Zeiss Axioplan 2 microscope, Carl Zeiss) or at 4 hours
with confocal laser scanning microscope (LSM 700,
Carl Zeiss). As control for non-specific labelling of the
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cells in a parallel experiment. For analysis with flow cy-
tometry, the A549 cells were washed twice with PBS,
treated with 0.25% trypsin-EDTA solution (Sigma-
Aldrich) to detach the cells and washed twice with 1%
FBS in PBS before acquired in a BD FACSAria flow cy-
tometry running BD FACS Diva version 6.0 Software
(BD Biosciences) and analyzed with the FlowJo Software
(Tree Star Inc., Ashland, OR, USA). For microscopy,
the cells were washed twice with PBS, fixed with 4%
formaldehyde solution for 15 minutes and washed
again twice with PBS. For the fluorescence microscopy
the cells were mounted with Vectashield (Vector
Laboratories Inc., Burlingame, CA, USA) supplemented
with 3% 7-Aminoactinomycin (7-ADD; BD Biosciences)
to label cell nuclei and for confocal microscopy cells
were mounted with ProLong® Gold Antifade Mountant
containing 4',6-diamidino-2-phenylindole (DAPI; Life
Technology).
Transfer of KIT protein and c-KIT mRNA to A549 cells
To determine if the KIT protein could be transferred via
exosomes, HMC-1 exosomes (80 μg) were added to
A549 cells (4 × 105) and the cells were incubated for 24
hours. The A549 cells were harvested, washed and the
total proteins were isolated using RIPA buffer (Cell Sig-
naling Technology, Danvers, Massachusetts, USA). As a
control, cells were treated with only media. The pres-
ence of KIT was determined using Western blot.
To determine if the c-KIT mRNA could be transferred
via exosomes, HMC-1 exosomes (80 μg) were added to
A549 cells (4 × 105). The cells were harvested at different
time points (30 minutes, 2, 4, 24 and 48 hours), washed
and isolation of total RNA was performed. Presence of
c-KIT mRNA was determined using reverse transcrip-
tion polymerase reaction (RT-PCR).
RT-PCR
Total RNA was isolated using miRCURY™ RNA Isolation
Kit (Exiqon¸Vedbaek, Denmark) according to the manu-
facturer’s protocol and as previously described [33].
Detection and quantity of RNA was determined using a
Bioanalyzer and RNA 6000 Nano chips according to the
manufacturer’s protocol (Agilent Technologies, Santa
Clara, CA, USA).
For examination of the c-KIT gene expression, 500 ng of
total RNA was converted into cDNA using RT2 first
Strand Kit (Qiagen, Hilden, Germany) according to the
manufacturer’s recommendations. For PCR amplification
1 μl of diluted cDNA (<500 ng) was used as a template
to make 50 μl reactions containing the reagents from Hot-
StarTaq Master Mix (Qiagen). KiCqStart™ primer pairs
(Sigma-Aldrich) used were as follows: GAPDH (forward)
5'-CTTTTGCGTCGCCAG-3', (reverse) 5'-TTGATGGCAACAATATCCAC-3'; c-KIT (forward) 5'-ACAAAACCA
GAAATCCTGAC-3', (reverse) 5'-CAGTTCCTGGACAA
AAATACC-3'. The length of the expected amplicon for
c-KIT and GAPDH were 109 and 139 base pair, respect-
ively. PCR amplification involved 30 cycles at 94°C for 30
seconds, 55°C for 45 seconds, and 72°C for 30 seconds.
PCR products were resolved on a 1.5% agarose gel (by
loading 5 μl of the PCR product) and detected utilizing
Gel Star® Nucleic Acid Gel Stain (Lonza, Rockland, ME,
USA) and a VersaDoc 4000 MP (Bio-Rad Laboratories,
Hercules, CA, USA).
Reverse migration assay
To evaluate the functional effect on lung epithelial cells
(A549) induced by HMC-1 derived exosomes, reverse
migration assay was performed using a 46 well Boyden
chamber (Neuroprobe Inc.). Briefly, A549 cells (32,500
cells/well) were added in the lower chamber and allowed
to adhere onto the gelatin (0.1%) coated polycarbonate
membrane by inverting the Boyden chamber upside
down (Neuroprobe Inc.). After 3 hours of incubation the
assembly was placed in correct orientation and exposed
to various HMC-1 exosomes dosage on the upper side
of the membrane for 12 hours. Migrating cells towards
the upper side of membrane were fixed in ethanol, and
stained with Giemsa (Histolab, Gothenburg, Sweden) and
images were acquired using a light microscope (Zeiss
Axioplan, Germany). Adhered cells, present on lower side
of membrane (non-migrated side), were wiped out care-
fully before imaging.
Detection of cell proliferation
Bromodeoxyuridine (BrdU) is incorporated into the
newly synthesized DNA strands of actively proliferating
cells. We therefore determined cell proliferation using a
BrdU labeling ELISA kit (Calbiochem, San Diego, CA,
USA) according to the manufacturer’s protocol. Shortly
A549 cells were seeded at the density of 1 × 105 in a
96-well plate and incubated overnight to allow cells to
attach to the plate. Cells received BrdU (20 μl) and 20
μg of either the HMC-1 exosomes or the control exo-
somes (isolated from NIH 3T3 cells) at the same time.
After 4 hours of incubation the absorbance was ob-
tained at dual wavelength (450 nm and 595 nm) with a
spectrophotometer (Spectra Max; Molecular Devices,
Sunnyvale, CA, USA). The results were normalized as
percent of control.
Western blot analysis
The cellular and exosomal proteins were separated by
SDS-PAGE, transferred to nitrocellulose membrane
(Bio-Rad Laboratories), blocked (5% BSA-TBST; bovine
serum albumin in TBS tween 20) for 2 hours. The mem-
brane were then incubated with the following primary
Xiao et al. Cell Communication and Signaling 2014, 12:64 Page 4 of 10
http://www.biosignaling.com/content/12/1/64rabbit anti-human antibodies: anti-CD81 (Santa Cruz
Biotechnology, Dallas, TX, USA), anti-calnexin (Santa
Cruz Biotechnology), anti-KIT (Abcam, Cambridge,
UK), anti-SCF (Santa Cruz Biotechnology), anti-PI3K
and anti-p-PI3K P85(T458)/P55(T199), anti-AKT and
anti-p-AKT(T308), anti-GSK3β and anti-p-GSK3β(S9),
and anti-cyclin D1 and anti-p-cyclin D1(T286) and pri-
mary mouse anti-human antibody; TSG101 (Abcam) di-
luted in 5% BSA -TBST at 4°C overnight. All antibodies
were purchased from Cell Signaling Technology Inc.,
(Danvers, MA, USA) unless stated otherwise. The mem-
brane was washed 3 × 5 minutes before incubation with
the secondary antibody for 2 hours. The secondary anti-
bodies used were goat F(ab)2 anti-rabbit IgG or donkey
anti-mouse IgG (HRP conjugated, Harlan Sera-Lab,
Loughborough, UK) diluted in 1% BSA-TBST. The
membrane was washed 3 × 5 minutes, before being ana-
lyzed with the Amersham™ECL Plus™ Western Blotting
Detection System (GE Healthcare, Buckinghamshire,
UK) and a VersaDoc 4000 MP (Bio-Rad Laboratories).
To normalize protein loading, identical loaded samples
were probed for GAPDH. Relative intensity was calcu-
lated as follows for p-PI3K, p-AKT and p-GSK3β; (phos-
phorylated protein/GAPDH)/(total protein/GAPDH),
and for cyclin D1; cyclin D1/GAPDH.
Statistical methods
The statistical analyses were performed using SPSS 16.0
statistical software (SPSS, Chicago, IL, USA). Student’s
t-test was used to analyze the difference between two
groups, and one-way ANOVA followed by Dunnett’s test
or Kruskal-Wallis test followed by Dunn´s multiple
comparisons test was employed for the comparisons
among three or more groups. To estimate correlation, a
Spearman ranked correlation test was performed. Data
are presented as the mean ± SEM for all statistical tests.
Results were considered to be statistically significant
when p ≤0.05.
Results
Identification of mast cell exosomes and their effect on
lung adenocarcinoma cells
After isolation of exosomes from the supernatant of cul-
tured HMC-1 cells, using ultracentrifugation, CD63
positive vesicular round structures could be visualized
by electron microscopy (Figure 1A). The protein fraction
isolated from the pellet after ultracentrifugation was
positive for the traditional exosome markers CD81 and
TSG101, while negative for a endoplasmic reticulum
protein, calnexin (Figure 1B), confirming our previous
data showing that HMC-1 cells can release exosomes
[12,34,35]. Furthermore, exosomes isolated from HEK
293 and NIH 3T3 cells were also positive for the exoso-
mal markers and negative for the endoplasmic reticulumprotein calnexin (Figure 1B). These exosomes were there-
fore considered to be appropriate to be used as control
exosomes in this study.
To examine whether exosomes from human mast cells
can be taken up by lung cancer cells, the HMC-1 exo-
somes were labeled with PKH67 dye and added to cul-
tures of A549 cells. Flow cytometry analysis (Figure 2A)
showed an increased fluorescence intensity of the A549
cells after the addition of mast cell-derived exosomes,
indicating cellular uptake. This uptake was reduced at
4°C, arguing that the uptake was an active process
(Figure 2B). The fluorescence of A549 cells was obvious
already two hours after addition of the stained exo-
somes, and increased over time (Figure 2C and D), indi-
cating initiation of uptake of the exosomes by A549
cells. The uptake of the fluorescent exosomes by the
A549 cells was also visualized using fluorescence micros-
copy (Figure 2E) and confocal microscopy (Figure 2F).
Additionally, fluorescence microscopy demonstrated that
control exosomes isolated from HEK 293 and NIH 3T3
cells were taken up by A549 cells in a similar manner as
HMC-1 exosomes (Figure 2G). This verifies their validity
to be used as control exosomes in the later functional
experiments.
To determine whether mast cell exosomes can influ-
ence lung adenocarcinoma, both proliferation and mi-
gration was assessed in the A549 cells in the presence of
HMC-1 exosomes. Firstly, HMC-1 exosomes were added
to A549 cells in culture for 4 hours in the presence of
BrdU to evaluate their capacity to influence proliferation.
The incorporation of BrdU was significantly increased
by 142% in the presence of HMC-1 exosomes compared
to the medium control and by 38% compared to the con-
trol exosomes, as quantified by an ELISA kit (Figure 3A).
Secondly, the A549 cells were seeded on the membrane of
the lower chamber with different doses of HMC-1 exo-
somes present in the upper chamber to evaluate the exo-
somal capacity to induce migration. Significantly more
cells migrated into the upper chamber in a dose response
dependent manner in the presence of HMC-1 exosomes,
with the highest doses being statistically significant com-
pere to the control and with a correlation coefficient of
0.91 (p <0.0001) (Figure 3B).
The presence of KIT protein in mast cell exosomes and
their shuttling to lung adenocarcinoma cells
The presence of the KIT protein in HMC-1 exosomes is
illustrated in Figure 4A. By contrast, the A549 cells had
no detectable KIT, as determined by Western blot. How-
ever, when HMC-1 exosomes were incubated with the
A549 cells for 24 hours, KIT could be detected in the
A549 cells by Western blot (Figure 4A). Stem cell factor
(SCF), the ligand for KIT, was however present in the
A549 cells, but absent in HMC-1 exosomes. By contrast,
Figure 1 Identification and characterization of HMC-1 exosomes. Exosomes were isolated using differential centrifugation. A) The electron
micrographs of the exosomes revealed rounded structures with a size of approximately 30–100 nm. Arrows indicate 10-nm gold-labeled
anti-CD63. The scale bar indicates 200 nm. B) Western blot analysis of exosomes derived from HMC-1 cells supernatant shows presence of the
common exosome proteins, CD81 and TSG101, but absence of the endoplasmic reticulum protein, calnexin. Also control exosomes isolated
from NIH 3T3 and HEK 293 cells were positive for TSG101 and CD81, but negative for calnexin. Cells were used as a control.
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somes, but only in the HMC-1 cells (Figure 3B). Further-
more, the c-KIT mRNA was not detected in the A549
cells at any of the time points analyzed. GAPDH were
used as positive controls, and GAPDH mRNA was
present in all samples, except in the HMC-1 exosomes
(Figure 3B). Our identification of KIT protein, but not
c-KIT mRNA, in the HMC-1 exosomes, and the transfer
of the protein to lung adenocarcinoma cells, suggests
that the presence of KIT in the A549 cells after exo-
somes depend on transfer of KIT protein, rather than
transfer of its mRNA (Figure 4A and B).
Mast cell exosomes activate the KIT-SCF signaling
pathway in recipient lung adenocarcinoma cells
Next, we sought to determine whether transfer of KIT
by HMC-1 exosomes could influence A549 intracellular
KIT-associated pathways, proposing a molecular explan-
ation for the observed enhanced proliferation seen in
Figure 3A. As shown in Figure 5A-E, we indeed found
that PI3K and its downstream targets, AKT, and GSK3β
showed increased phosphorylation in A549 cells when
HMC-1 exosomes were added, compared to media
alone or control exosomes. However, the total amounts
of these three proteins were unchanged according to
the Western blot analysis. When PI3K is phosphory-
lated and thus activated it phosphorylates AKT, which
in turn inactivates GSK3β by phosphorylating the S9
residue on GSK3β. Cyclin D1 is a cell-cycle regulator
downstream of GSK3β and is inhibited by GSK3β.
Therefore an increase in deactivation of GSK3β by
phosphorylation will lead to an increase in cyclin D1,
which will result in cells moving from the G1 phase into
the S phase of the cell cycle. Importantly, cyclin D1, was
indeed increased in A549 cells after the addition of
HMC-1 exosomes, which then can be associated to in-
creased proliferation of the lung adenocarcinoma cells.When cyclin D1 is phosphorylated it is transported
out of the nucleus and degraded, and as shown in
Figure 5A, this inactivated stage is attenuated by HMC-
1 exosomes, which thus further can enhance the activa-
tion of cyclin D1.
These experiments together indicate that KIT positive
exosomes from HMC-1 cells have the capability to in-
duce PI3K/AKT signaling and influence cell proliferation
in A549 cells.
Discussion
Tumor tissues include many different cells, and little
is known how they interact in a clinical situation to
influence cancer development. It has been suggested
that exosomes and other extracellular vesicles can
shuttle many molecules between cells, which is a
process likely to be very active in cell-to-cell signaling
in tumors. Tumor tissue also contains many inflamma-
tory cells, and it is known that mast cells can be part
of the tumor microenvironment in lung tumors such
as non-small cell lung cancer. However, little is known
how mast cells might act to specifically promote
cancer proliferation. Here, we found that exosomes
derived from the human mast cell line, HMC-1, con-
tain the receptor KIT, which can be transferred to
lung adenocarcinoma cells by exosomes. In particular,
we show that mast cells release exosomes with typical
exosome markers such as TSG101 and CD81. The
mast cell exosomes are rapidly taken up by lung adeno-
carcinoma cells (A549 cells), a process that peaks after
approximately 12 hours. Importantly, the exosomes re-
leased by human mast cells contain the natural growth
factor receptor KIT, but not c-KIT mRNA. Addition of
mast cell exosomes containing KIT enhance prolifera-
tion and migration of the lung adenocarcinoma cells,
and enhance the KIT-SCF signaling pathway activity.
Overall, these data suggest that exosomes from mast cell
Figure 2 Uptake of human mast cell exosomes by human lung adenocarcinoma cells. Twenty microgram of the PKH67-labelled HMC-1,
HEK 293 or NIH 3T3 exosomes, or a PKH67-PBS control were added per 2 ×105 A549 cells and incubated at 37°C or 4°C for 1–48 hours. The
uptake of the fluorescently labelled exosomes by A549 was detected with flow cytometry (at all the time points), fluorescence microscopy (at the
12 hour time point) and confocal microscopy (at the 4 hour time point). A) Representative graph of uptake at 4 hours at 37° detected with flow
cytometry. Black curve, control cells; blue curve, PKH67-PBS control; green curve, PKH67-labelled HMC-1 exosomes. B) Representative graph of
uptake at 8 hours detected with flow cytometry. Black curve, control cells; red curve, PKH67-labelled HMC-1 exosomes at 4°C; green curve,
PKH67-labelled HMC-1 exosomes at 37°C. C and D) Percent positive cells and relative fluorescence intensity (rFI) data for all time points determined
with flow cytometry are shown as mean ± SEM (n =3). E) Uptake of PKH67-PBS control and PKH67-labelled exosomes at 37°C imaging with
fluorescence microscopy. Nuclei were stained with 7-AAD (red). F) Uptake of PKH67-labelled exosomes at 37°C imaging with confocal
microscopy (bar is indicating 20 μm). Nuclei were stained with DAPI (blue). G) Uptake of PKH67-labelled NIH 3T3- and HEK 293-derived
exosomes at 37°C imaging with fluorescence microscopy. Nuclei were stained with 7-AAD (red).
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tatively by enhancing KIT-SCF signaling in tumor cells.
In this study, we confirm the ability of the mast cell line
HMC-1 to release exosomes into their microenvironment[34], and extend these findings by demonstrating their
ability to be taken up by human lung adenocarcinoma
cells (A549 cells). The observed uptake is rapid, as
more than 70% of cells have taken up some exosomes
Figure 3 Mast cell-derived exosomes induce proliferation and migration in A549 cells. (A) BrdU cell proliferation assays were used to
detect proliferating A549 cells after co-culturing for 4 hours with HMC-1 exosomes or control exosomes (derived from NIH 3T3 cells). *P <0.05.
(B) A549 cells were added to the lower chamber of a Boyden chamber (32 500 cells/well). To the upper chamber 30 μl of the different doses of
HMC-1 exosomes were added. Media was used as a control. After 12 hours the number of cells migrated to the lower chamber of the 8 μm
pore-sized membrane were analyzed by taking photos and counting the number of cells per visual field. Kruskal-Wallis test followed by Dunn’s
multiple comparisons test were used to determine significant differences where all concentrations were only compared to the control. Spearman’s
rank correlation coefficient was 0.91 (p <0.0001). p-values; * <0.05, *** <0.001.
Figure 4 HMC-1 exosomes transfer KIT protein to A549 cells. Eighty microgram of HMC-1 exosomes were added per 4 ×105 A549 cells
and incubated at 37°C for 24 hours for the Western blot experiments (A) and for 30 minutes - 48 hours for the RT-PCR experiments (B). A)
Western blot confirmed the presence of the KIT protein in HMC-1 exosomes, but not in the A549 cells. SCF expression was detected in
A549 cell but not in the HMC-1 exosomes. SCF and KIT were both detected in A549 cells 24 hours after the addition of HMC-1
exosomes. B) RT-PCR showed that c-KIT mRNA was present in HMC-1 cells, whereas it was absent in both HMC-1 exosomes and A549
cells. GAPDH mRNAs were detected as positive control and were detected in all samples except in HMC-1 exosomes.
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Figure 5 Mast cell-derived exosomes can activate the KIT-SCF signaling pathway in A549 cells. A549 cells treated with exosomes from
control cells (HEK 293) or HMC-1 cells were analyzed using Western blot. Phosphorylated and total PI3K, AKT, GSK3β and cyclinD1 were measured
by Western blot and to normalize protein loading, samples were also probed for GAPDH. (A). Relative intensity was calculated as follows for
p-PI3K (B), p-AKT (C) and p-GSK3β (D); (phosphorylated protein/GAPDH)/(total protein/GAPDH), and for cyclin D1 (E); cyclin D1/GAPDH. All the
above data are representative of three independent experiments (n =3). *P <0.05 and **P <0.01.
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cells are positive for exosomes. However, the uptake
continues over time, measured as relative fluorescent
intensity, and peaks at 12–24 hours after addition of
exosomes. This time course of uptake is slightly faster
then what we have previously reported [34].
Less is known about the functionality of mast cell
exosomes. In the current experiments, we have de-
scribed the presence of the KIT tyrosine kinase receptor
in mast cell exosomes, a molecule that sometimes, but
not always, is expressed in lung tumor tissues [36].
Importantly, we were unable to detect the c-KIT
mRNA in the exosomes, suggesting that any functional
shuttling of this molecule between cells is at the pro-
tein level. KIT was present in the lung adenocarcinoma
cell line after addition of mast cell exosomes, docu-
mented using Western blot analysis. KIT has beenconsidered to be a marker of progenitor cells [37] and
can be more expressed in preneoplastic tissue and tu-
mors, such as gastrointestinal stromal tumor (GIST)
[38], small cell lung cancer (SCLC) [39], colorectal
cancer [40,41] and pancreatic neoplasms [42]. KIT has
also been implied in non-small cell lung cancer mor-
tality, indicating that it may influence tumor growth
and metastasis [23].
In the present study we confirm that addition of KIT-
containing mast cell exosomes can enhance the prolifer-
ation of lung adenocarcinoma cells, shown as uptake
of BrdU. A similar finding was recently published in
which patient tumor exosomes containing KIT protein
could transfer that protein to gastrointestinal stromal
tumor cells and smooth muscle cells in vitro, which
enhanced signs of invasiveness [26]. In our study, we
have also included an appropriate exosome control in all
Xiao et al. Cell Communication and Signaling 2014, 12:64 Page 9 of 10
http://www.biosignaling.com/content/12/1/64experiments, and provided evidence that the KIT con-
taining mast cell exosomes can enhance the KIT-SCF
signaling pathways intracellularly.
We could here detect enhanced KIT-SCF signaling
pathways, by up-regulation of phosphorylated PI3K as
well as AKT and GSK3β. These data suggest, collectively,
that the KIT containing mast cell exosomes indeed can
activate cascades downstream from the tyrosine kinase
receptor KIT. We therefore propose that the tumor cell-
produced SCF can help tumor growth via a PI3K
dependent pathway, if mast cell KIT-containing exo-
somes are delivered to the cells. Mast cell exosomes car-
rying KIT may bind SCF molecules produced by the
tumor cells, and activate the cell in an autocrine fashion
via PI3K and AKT. It is known that AKT can enhance
tumor growth, by phosphorylating and inactivating
GSK3β. This can in turn lead to a decrease in the nu-
clear exclusion of cyclin D1, which thereby allow the
molecule to functioning as a cell cycling promoter by
driving the cells from G1 phase to S phase [43,44]. Over-
all, our data imply that mast cell KIT-containing exo-
somes can influence the PI3K signaling pathway in
recipient tumor cells.
There are of course shortcomings with in vitro studies
such as our, as results may or may not be applicable for
clinical disease. However, in a previous clinical study of
non-small cell lung tumors, we found that KIT positivity
was associated with higher mortality [23].
Our current series of experiments have demonstrated
the release of KIT-containing exosomes from a human
mast cell line, and shows that these exosomes can be
taken up by lung adenocarcinoma cells. This leads to en-
hanced proliferation in recipient tumor cells, by the acti-
vation of the PI3K signaling pathway. Future work can
highlight the molecular mechanisms leading to the re-
lease of exosomes from mast cells, and their uptake into
tumor cells. Further, it is essential to understand the di-
verse possibilities of exosome-based intercellular com-
munication among many different types of cells in the
tumor microenvironment.
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